{
    "clinical_study": {
        "@rank": "30225", 
        "arm_group": [
            {
                "arm_group_label": "Sleep Induction", 
                "arm_group_type": "Experimental", 
                "description": "7.5 grams of sodium oxybate"
            }, 
            {
                "arm_group_label": "Sleep Deprivation", 
                "arm_group_type": "Experimental", 
                "description": "Sleep deprivation for up to 36 hours with no naps or other sleep periods"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "Participant will sleep as normal under the same controlled conditions in a clinical research unit"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to change the concentration of amyloid-beta in human\n      cerebrospinal fluid (CSF) through modulation of the sleep-wake cycle."
        }, 
        "brief_title": "Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction", 
        "condition": "Changing CSF Amyloid-beta Levels With Sleep Modification", 
        "condition_browse": {
            "mesh_term": "Sleep Deprivation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  cognitively normal or CDR 0\n\n          -  negative for amyloid deposition by PET Pittsburgh Compound-B (PIB) imaging or CSF\n             amyloid-beta-42 concentration\n\n               -  18\n\n        Exclusion Criteria:\n\n          -  diagnosis of a sleep disorder such as sleep apnea, narcolepsy, or restless leg\n             syndrome\n\n          -  positive ambulatory sleep study for obstructive sleep apnea (AHI > 5 respiratory\n             events per hour) that will be performed as part of initial screening prior to\n             enrollment\n\n          -  Clinical Dementia Rating (CDR) > 0\n\n          -  tremor or other neurologic injury in the non-dominant upper extremity (such as stroke\n             or tremor) that would prevent the use of actigraphy\n\n          -  current sleep walking or other sleep parasomnia\n\n          -  diagnosis and treatment of stroke, myocardial infarction or heart attack,\n\n          -  coronary artery disease, atrial fibrillation, or congestive heart failure\n\n          -  diagnosis and treatment of asthma or Chronic Obstructive Pulmonary Disease (COPD)\n\n          -  diagnosis and treatment of bipolar disorder, major depression, or Schizophrenia\n\n          -  current urinary or fecal incontinence\n\n          -  currently on a low salt diet\n\n          -  diagnosis and treatment of a neurologic disorder such as Parkinson's disease,\n             epilepsy, multiple sclerosis\n\n          -  currently taking any blood thinner medications such as warfarin, Plavix, or Aspirin\n\n          -  kidney disease resulting in renal impairment\n\n          -  liver disease resulting in hepatic dysfunction\n\n          -  Pregnancy\n\n          -  currently taking sedating medications such as benzodiazepines"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063217", 
            "org_study_id": "201304030", 
            "secondary_id": "P50AG005681-30"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sleep Induction", 
                "intervention_name": "Sodium Oxybate", 
                "intervention_type": "Drug", 
                "other_name": "Xyrem"
            }, 
            {
                "arm_group_label": "Sleep Deprivation", 
                "description": "36hr sleep deprivation", 
                "intervention_name": "Sleep deprivation", 
                "intervention_type": "Behavioral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sodium Oxybate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 12, 2014", 
        "location": {
            "contact": {
                "email": "mclelandj@neuro.wustl.edu", 
                "last_name": "Jennifer McLeland, MSW, MA", 
                "phone": "314-747-3819"
            }, 
            "contact_backup": {
                "email": "toedebuschc@neuro.wustl.edu", 
                "last_name": "Cristina Toedebusch, BS", 
                "phone": "314-747-0646"
            }, 
            "facility": {
                "address": {
                    "city": "Saint Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63108"
                }, 
                "name": "Washington University Medical School"
            }, 
            "investigator": {
                "last_name": "Brendan Lucey, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction", 
        "overall_contact": {
            "email": "mclelandj@neuro.wustl.edu", 
            "last_name": "Jennifer McLeland, MSW, MA", 
            "phone": "314-747-3819"
        }, 
        "overall_contact_backup": {
            "email": "toedebuschc@neuro.wustl.edu", 
            "last_name": "Cristina Toedebusch, BS", 
            "phone": "314-747-0646"
        }, 
        "overall_official": {
            "affiliation": "Washington University Medical School", 
            "last_name": "Brendan Lucey, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in CSF amyloid beta concentration during sleep induction and sleep deprivation", 
            "safety_issue": "No", 
            "time_frame": "36 hours of CSF collection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063217"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institutes of Health (NIH)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "National Institute on Aging (NIA)", 
                    "agency_class": "NIH"
                }
            ], 
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}